Buy Semaglutide Online

Healthon offers a medically supervised program where licensed providers evaluate whether treatment options, including compounded GLP-1 medications, may be appropriate for your individual needs. Here’s how it works:

1. Complete a Medical Intake Form: Submit your health history and wellness goals through our secure platform.
2. Provider Review: A board-certified physician will review your information and determine eligibility, either via live (SYNC) or asynchronous (ASYNC) telehealth, depending on state regulations.
3. Prescription, if appropriate: If your provider determines that treatment is suitable, a prescription may be issued for a compounded semaglutide preparation. Note: Compounded medications are not FDA-approved. They are prepared in licensed compounding pharmacies and may be considered when FDA-approved products are unavailable or medically unsuitable.
4. Convenient Delivery: Medications, if prescribed, are shipped directly to your home from a licensed pharmacy.

Healthon offers access to prescription-based GLP-1 therapies as part of its medical weight management program for eligible patients.

Semaglutide and Tirzepatide may be prescribed in compounded form by licensed pharmacies for patients when FDA-approved options are unavailable or not medically appropriate. Compounded medications are not FDA-approved, but are prepared in state-licensed pharmacies under applicable regulations.

All treatments are prescribed based on clinical need, safety considerations, and individual patient goals through a licensed medical provider.

Healthon works only with licensed compounding pharmacies that follow applicable state and federal regulations. These pharmacies may use third-party testing to assess quality.

Pricing is transparent and includes your virtual consultation, medication if prescribed, and clinical support. Costs begin at $155/month for Compounded Semaglutide and $275/month for Compounded Tirzepatide. Final eligibility and treatment depend on provider evaluation.

These all-inclusive costs cover your virtual consultation, medication, and ongoing support, making it a cost-effective way to start your semaglutide weight loss journey.

Commercial-grade semaglutide (Ozempic®, Wegovy®) is FDA-approved, with standardized dosing and published safety and efficacy data.
Compounded semaglutide, by contrast, is not FDA-approved. It is prepared by licensed compounding pharmacies for individual patients when a prescriber determines FDA-approved options are not suitable.

Semaglutide belongs to a class of medications known as GLP-1 receptor agonists. Published clinical studies on FDA-approved semaglutide products have shown benefits in appetite regulation and blood sugar control. Compounded semaglutide has not been reviewed or approved by the FDA for safety or efficacy. Providers may consider compounded formulations when FDA-approved options are unavailable or unsuitable.

Healthon works only with licensed compounding pharmacies that follow applicable regulations.

Obesity is linked to chronic conditions such as diabetes and heart disease. FDA-approved GLP-1 medications have been studied extensively in this context.

Healthon’s GLP-1 program supports weight loss in a sustainable way, helping patients reduce health risks and improve their quality of life.

Apovian, C. M., et al. (2015). Pharmacological management of obesity: An endocrine society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 100(2), 342-362.

World Health Organization (2021). Obesity and overweight.

Both medications regulate hunger hormones to promote consistent and long-term fat loss. Tirzepatide activates two hormones (GLP-1 and GIP), while Semaglutide focuses on GLP-1 alone, yet both have been clinically validated to support double-digit weight loss percentages.

Clinical studies on FDA-approved semaglutide and tirzepatide have shown significant weight reduction in participants. Compounded preparations are not FDA-approved, and outcomes may vary.

Wilding, J. P. H., et al. (2021). Once-weekly Semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.

Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387, 205-216.

Both semaglutide and tirzepatide are GLP-1-based medications prescribed for chronic weight management, but they work through slightly different mechanisms:

Published studies of FDA-approved semaglutide and tirzepatide medications have reported average weight reductions ranging from 15% to 22% depending on the study.

Prescription of either medication depends on a patient’s medical history, goals, and response to treatment, and is determined by a licensed healthcare provider.

Clinical studies of FDA-approved GLP-1 medications have reported weight changes typically beginning within the first 3 months, with greater reductions over 6–12 months when paired with diet and lifestyle changes. Individual results may vary.

Wilding, J. P. H., et al. (2021). Once-weekly Semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002.

Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387, 205-216.

Most side effects are mild and tend to improve over time. Common ones include:

• Nausea: This is the most common side effect and usually occurs when starting the medication or after increasing the dose. It generally improves over time.
• Vomiting
• Diarrhea
• Constipation
• Indigestion
• Decreased appetite

Serious risks such as pancreatitis or gallbladder issues have been reported. Compounded semaglutide has not been evaluated by the FDA for safety or effectiveness; however, side effects may be similar given the same active ingredient.

Injection Site Reactions:

• Redness or irritation at the injection site is possible but usually mild.

FDA Prescribing Information for Semaglutide (Ozempic)

FDA Prescribing Information for Tirzepatide (Mounjaro)